MS walking study: ocrevus vs. standard drugs
NCT ID NCT04387734
First seen Jan 08, 2026 · Last updated May 25, 2026 · Updated 19 times
Summary
This study looks at whether a year of treatment with Ocrevus can improve walking and balance in people with relapsing multiple sclerosis, compared to other standard medications. Sixty adults aged 18-65 who can walk at least 25 feet will be split into two groups and followed for one year with walking tests and brain scans. The goal is to see if Ocrevus offers better mobility benefits than other disease-modifying treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Georgia State University
Atlanta, Georgia, 30303, United States
-
Multiple Sclerosis Center of Atlanta
Atlanta, Georgia, 30327, United States
Conditions
Explore the condition pages connected to this study.